Search
Investigational Products
SALIX is committed to the development of innovative treatments for gastrointestinal (GI) diseases and other disorders that provide healthcare professionals (HCPs) and patients with effective treatment options.
Details for the molecules currently included in our pipeline are provided in the table below. See table footnotes for links to the individual clinical trials.
*For more information on clinical trials of rifaximin soluble solid dispersion in hepatic encephalopathy, click here.
†For more information on clinical trials of rifaximin extended-release/delayed extended release tablets in sickle cell disease, click here.
‡For more information on clinical trials of rifaximin 550 mg tablets in severe hepatic impairment and hepatic encephalopathy, click here.
§For more information on clinical trials of amiselimod (MT-1303) in mild to moderate ulcerative colitis, click here.
¶For more information on clinical trials of plecanatide tablets in IBS-C in pediatric patients, click here.
This page provides information on investigational assets as of July 1, 2023. The safety and efficacy of these investigational assets have not been established.
There is no guarantee that the outcomes of the studies shown here will result in approval by a regulatory authority.
Search
*Required field.
Select a product*
Select a therapeutic area*
Enter keyword(s)